NASDAQ:CDXC ChromaDex (CDXC) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free CDXC Stock Alerts $2.96 -0.02 (-0.67%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$2.85▼$3.0250-Day Range$2.76▼$4.0952-Week Range$1.25▼$4.65Volume238,956 shsAverage Volume259,832 shsMarket Capitalization$223.60 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get ChromaDex alerts: Email Address ChromaDex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside102.7% Upside$6.00 Price TargetShort InterestHealthy3.49% of Float Sold ShortDividend StrengthN/ASustainability-1.62Upright™ Environmental ScoreNews Sentiment0.35Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.02) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.47 out of 5 starsMedical Sector267th out of 913 stocksMedicinals & Botanicals Industry1st out of 12 stocks 3.5 Analyst's Opinion Consensus RatingChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChromaDex has only been the subject of 2 research reports in the past 90 days.Read more about ChromaDex's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.49% of the float of ChromaDex has been sold short.Short Interest Ratio / Days to CoverChromaDex has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in ChromaDex has recently decreased by 0.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldChromaDex does not currently pay a dividend.Dividend GrowthChromaDex does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChromaDex has received a 58.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Dietary supplements" products. See details.Environmental SustainabilityThe Environmental Impact score for ChromaDex is -1.62. Previous Next 1.9 News and Social Media Coverage News SentimentChromaDex has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ChromaDex this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for CDXC on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ChromaDex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.64% of the stock of ChromaDex is held by insiders.Percentage Held by InstitutionsOnly 15.41% of the stock of ChromaDex is held by institutions.Read more about ChromaDex's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ChromaDex are expected to grow in the coming year, from ($0.02) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ChromaDex is -59.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ChromaDex is -59.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChromaDex has a P/B Ratio of 7.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ChromaDex's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About ChromaDex Stock (NASDAQ:CDXC)ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Read More CDXC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXC Stock News HeadlinesJune 14, 2024 | americanbankingnews.comChromaDex (NASDAQ:CDXC) Rating Reiterated by Roth MkmJune 14, 2024 | americanbankingnews.comHead to Head Contrast: Pervasip (OTCMKTS:PVSP) and ChromaDex (NASDAQ:CDXC)June 13, 2024 | businesswire.comChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)June 7, 2024 | businesswire.comChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)June 4, 2024 | businesswire.comChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024May 27, 2024 | msn.comCompare with Chromadex Corp (CDXC)May 23, 2024 | businesswire.comChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 22, 2024 | finance.yahoo.comChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year AwardMay 22, 2024 | businesswire.comChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year AwardMay 10, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue EstimatesMay 9, 2024 | markets.businessinsider.comChromadex Poised for Continued Growth; Selvaraju Reiterates Buy Rating with $6 TargetMay 9, 2024 | finance.yahoo.comChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...May 8, 2024 | investorplace.comCDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | msn.comChromaDex GAAP EPS of -$0.01 in-line, revenue of $22.2M misses by $1.41MMay 8, 2024 | finance.yahoo.comChromaDex Corporation Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comChromaDex is about to announce its earnings — here's what to expectMay 6, 2024 | finance.yahoo.comAn Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 43% UndervaluedMay 1, 2024 | finance.yahoo.comChromaDex Corporation (CDXC)April 30, 2024 | finance.yahoo.comChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementApril 30, 2024 | businesswire.comChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementApril 25, 2024 | businesswire.comChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®April 24, 2024 | businesswire.comChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024April 23, 2024 | businesswire.comChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketApril 17, 2024 | msn.comChromaDex (CDXC) Price Target Increased by 9.92% to 6.60See More Headlines Receive CDXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/17/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:CDXC CUSIPN/A CIK1386570 Webwww.chromadex.com Phone(310) 388-6706Fax949-419-0294Employees106Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+102.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,940,000.00 Net Margins-4.24% Pretax Margin-4.24% Return on Equity-12.61% Return on Assets-6.54% Debt Debt-to-Equity RatioN/A Current Ratio2.52 Quick Ratio1.88 Sales & Book Value Annual Sales$83.57 million Price / Sales2.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book7.79Miscellaneous Outstanding Shares75,540,000Free Float68,257,000Market Cap$223.60 million OptionableOptionable Beta1.90 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Frank Louis Jaksch Jr. (Age 56)Co-Founder & Chairman Comp: $70kMr. Robert N. Fried (Age 64)CEO & Director Comp: $768.96kMs. Brianna Gerber (Age 43)Chief Financial Officer Comp: $482.15kDr. Andrew Shao Ph.D.Senior Vice President of Global Regulatory & Scientific AffairsHeather Van BlarcomSenior VP of Legal & Corporate SecretaryAlex WorshamVice President of Global Marketing & CommunicationsMr. David KroesSenior Vice President of People MattersMs. Chu YanManaging Director of Asia PacificMr. Jason CampbellSenior Vice President of Business DevelopmentKendall KnyschHead of Media Relations & PartnershipsMore ExecutivesKey CompetitorsMenlo TherapeuticsNASDAQ:FOMXUSANA Health SciencesNYSE:USNACanopy GrowthNASDAQ:CGCMind Medicine (MindMed)NASDAQ:MNMDbioteNASDAQ:BTMDView All CompetitorsInsiders & InstitutionsPerritt Capital Management Inc.Bought 40,000 shares on 5/15/2024Ownership: 0.053%Lazard Asset Management LLCBought 12,592 shares on 5/15/2024Ownership: 0.017%Acadian Asset Management LLCBought 19,461 shares on 5/10/2024Ownership: 0.026%Oppenheimer & Co. Inc.Sold 8,000 shares on 5/7/2024Ownership: 0.026%SG Americas Securities LLCBought 15,423 shares on 5/7/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions CDXC Stock Analysis - Frequently Asked Questions Should I buy or sell ChromaDex stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDXC shares. View CDXC analyst ratings or view top-rated stocks. What is ChromaDex's stock price target for 2024? 2 Wall Street analysts have issued 12-month price objectives for ChromaDex's stock. Their CDXC share price targets range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 102.7% from the stock's current price. View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts. How have CDXC shares performed in 2024? ChromaDex's stock was trading at $1.43 at the start of the year. Since then, CDXC shares have increased by 107.0% and is now trading at $2.96. View the best growth stocks for 2024 here. When is ChromaDex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our CDXC earnings forecast. How were ChromaDex's earnings last quarter? ChromaDex Co. (NASDAQ:CDXC) posted its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company earned $22.15 million during the quarter, compared to analyst estimates of $22.35 million. ChromaDex had a negative net margin of 4.24% and a negative trailing twelve-month return on equity of 12.61%. What guidance has ChromaDex issued on next quarter's earnings? ChromaDex issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $96.9 million-, compared to the consensus revenue estimate of $97.6 million. What is Robert Fried's approval rating as ChromaDex's CEO? 13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend. What other stocks do shareholders of ChromaDex own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL). Who are ChromaDex's major shareholders? ChromaDex's stock is owned by a variety of institutional and retail investors. Top institutional investors include Perritt Capital Management Inc. (0.05%), Oppenheimer & Co. Inc. (0.03%), Acadian Asset Management LLC (0.03%), SG Americas Securities LLC (0.02%), Lazard Asset Management LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brianna Gerber, Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Robert N Fried and Steven D Rubin. View institutional ownership trends. How do I buy shares of ChromaDex? Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDXC) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ChromaDex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.